Crossref
Economic Evaluation of Molnopyravir, Paxlovid and Fluvoxamine in Treatment of COVID-19 Patients in Iran
Iranian Journal of Health Insurance · 01.03.2024 · 6 (4) · 288-299
DOI: 10.66224/ihio.6.4.288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Iranian Journal of Health Insurance, online erschienen am 01.03.2024. Verfasst von Pedram Nourizadeh Tehrani und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Tehrani, P. N., Dolatabad, M. A., & Daroudi, R. (2024). Economic Evaluation of Molnopyravir, Paxlovid and Fluvoxamine in Treatment of COVID-19 Patients in Iran. Iranian Journal of Health Insurance, 6(4), 288-299. https://doi.org/10.66224/ihio.6.4.288
Vancouver
Tehrani PN, Dolatabad MA, Daroudi R. Economic Evaluation of Molnopyravir, Paxlovid and Fluvoxamine in Treatment of COVID-19 Patients in Iran. Iranian Journal of Health Insurance. 2024;6(4):288-299. doi:10.66224/ihio.6.4.288
BibTeX
@article{Tehrani2024,
author = {Tehrani, Pedram Nourizadeh and Dolatabad, Mobarakeh Alipanah and Daroudi, Rajabali},
title = {Economic Evaluation of Molnopyravir, Paxlovid and Fluvoxamine in Treatment of COVID-19 Patients in Iran},
journal = {Iranian Journal of Health Insurance},
year = {2024},
volume = {6},
number = {4},
pages = {288--299},
doi = {10.66224/ihio.6.4.288}
}
EUVIMED